Cargando…
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Therapeutically actionable molecular alterations are widely distributed across cancer types. The National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH) trial was designed to evaluate targeted therapy antitumor activity in underexplored cancer types. Tumor biopsy specimens were a...
Autores principales: | Flaherty, Keith T., Gray, Robert J., Chen, Alice P., Li, Shuli, McShane, Lisa M., Patton, David, Hamilton, Stanley R., Williams, P. Mickey, Iafrate, A. John, Sklar, Jeffrey, Mitchell, Edith P., Harris, Lyndsay N., Takebe, Naoko, Sims, David J., Coffey, Brent, Fu, Tony, Routbort, Mark, Zwiebel, James A., Rubinstein, Larry V., Little, Richard F., Arteaga, Carlos L., Comis, Robert, Abrams, Jeffrey S., O’Dwyer, Peter J., Conley, Barbara A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676882/ https://www.ncbi.nlm.nih.gov/pubmed/33048619 http://dx.doi.org/10.1200/JCO.19.03010 |
Ejemplares similares
-
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
por: Flaherty, Keith T, et al.
Publicado: (2020) -
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023) -
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023) -
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022) -
Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with
HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ)
adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821–1830]
por: Jhaveri, K.L., et al.
Publicado: (2021)